LICENSE FOR FOREIGN FILING UNDER
`Title 35, United States Code, Section 184
`Title 37, Code of Federal Regulations, 5.11 & 5.15
`
`GRANTED
`
`The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where
`the conditions for issuance of a license have been met, regardless of whether or not a license may be required as
`set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier
`license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The
`date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under
`37 CFR 5.13 or 5.14.
`
`This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless
`it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This
`license is not retroactive.
`
`The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter
`as imposed by any Government contract or the provisions of existing laws relating to espionage and the national
`security or the export of technical data. Licensees should apprise themselves of current regulations especially with
`respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of
`State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and
`Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of
`Treasury (31 CFR Parts 500+) and the Department of Energy.
`
`NOT GRANTED
`
`No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12,
`if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed
`from the filing date of this application and the licensee has not received any indication of a secrecy order under 35
`U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).
`
`SelectUSA
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for
`business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources
`and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to
`promote and facilitate business investment. SelectUSA provides information assistance to the international investor
`community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states,
`and regions competing for global investment; and counsels U.S. economic development organizations on investment
`attraction best practices. To learn more about why the United States is the best country in the world to develop
`technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.aov or call
`+1-202-482-6800.
`
`page 3 of 3
`
`0411
`
`EXHIBIT 1004 (Part 3 of 5)
`
`

`

`Electronic Acknowledgement Receipt
`
`EFSID:
`
`Application Number:
`
`18616805
`
`14222478
`
`International Application Number:
`
`Confirmation Number:
`
`9616
`
`Title of Invention:
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN
`COMPONENTS
`
`First Named Inventor/Applicant Name:
`
`Andrew Acheampong
`
`Customer Number:
`
`51957
`
`Filer:
`
`Laura Lee Wine/Ken Dinh
`
`Filer Authorized By:
`
`Laura Lee Wine
`
`Attorney Docket Number:
`
`17618CON6CON1 (AP)
`
`Receipt Date:
`
`Filing Date:
`
`Time Stamp:
`
`28-MAR-2014
`
`16:55:06
`
`Application Type:
`
`Utility under 35 USC 111(a)
`
`Payment information:
`
`Submitted with Payment
`File Listing:
`Document
`Number
`
`Document Description
`
`1
`
`Non Patent Literature
`
`Warnings:
`
`Information:
`
`no
`
`File Name
`
`File Size( Bytes)/
`Message Digest
`
`Multi
`Part /.zip
`
`Pages
`(ifappl.)
`
`PedersenExpertOpin1415_143
`6_2001.pdf
`
`4262912
`
`0ffbacdd587d316724d2c00a7e64fcdbc6ed
`49e4
`
`no
`
`22
`
`0412
`
`

`

`2
`
`Non Patent Literature
`
`Phillips_CydosporineJOCP1_20
`OO.pdf
`
`1385594
`
`63acdf4c243d41621f7001e9c76dbf167d4e
`c51d
`
`no
`
`10
`
`Warnings:
`
`Information:
`
`3
`
`Non Patent Literature
`
`Present_1993.pdf
`
`no
`
`4
`
`1624134
`
`baefc9d58e2e27ac5b6a99bd9151eb6a41e
`80d81
`
`Warnings:
`
`Information:
`
`4
`
`Non Patent Literature
`
`Restasis_lncreasing_tear_Prod
`uction_2009.pdf
`
`332259
`
`0a1285bcf642f927562ba180ba3ba5446eb
`2afe4
`
`no
`
`3
`
`Warnings:
`
`Information:
`
`5
`
`Non Patent Literature
`
`RestasisProductlnfoSheets.pdf
`
`no
`
`5
`
`56377
`
`844b6588f9ea989c6c37ffe4c0b220c950ffa
`dea
`
`Warnings:
`
`Information:
`
`6
`
`Non Patent Literature
`
`Robinsonaustraliandentaljourn
`al206_211_2003.pdf
`
`768117
`
`no
`
`6
`
`798558b0fd44a086f71fe1076b47333898b7
`e976
`
`Warnings:
`
`Information:
`
`7
`
`Non Patent Literature
`
`RudingerPeptideHormones1_7
`_1976.pdf
`
`2488192
`
`b6fc18b6ad98c34de41f2d461a1f5736500b
`e985
`
`no
`
`1 1
`
`Warnings:
`
`Information:
`
`8
`
`Non Patent Literature
`
`Sall_2000.pdf
`
`no
`
`9
`
`208829
`
`065c18613831a6d2cf5a88066e70ae03daa
`e1b29
`
`Warnings:
`
`Information:
`
`9
`
`Non Patent Literature
`
`SandbornGastroenterologyl 42
`9_1435_1994.pdf
`
`872000
`
`no
`
`7
`
`730e8bcd0c58076ab6f0163f4551 eff0f507e
`5c6
`
`Warnings:
`
`Information:
`
`10
`
`Non Patent Literature
`
`Sandborn_1993.pdf
`
`no
`
`6
`
`1969241
`
`10802f861668ec206f085b7aa854a3b76526
`cf59
`
`Warnings:
`
`Information:
`
`0413
`
`

`

`1 1
`
`Non Patent Literature
`
`SchwabPharmacokinet723_751
`_2001.pdf
`
`4260474
`
`decfedf8ccd3394e49e7e8a02f40d13d5023
`683f
`
`no
`
`30
`
`Warnings:
`
`Information:
`
`1 2
`
`Non Patent Literature
`
`Secchi_1990.pdf
`
`no
`
`5
`
`3200224
`
`Warnings:
`
`Information:
`
`8a65624bb284fb7ad8fc4cc8ba5ee1a92ffe
`4b94
`
`166579
`
`13
`
`Non Patent Literature
`
`Small_1999.pdf
`
`no
`
`1
`
`Warnings:
`
`Information:
`
`a6352b5109a02b19264b6b81164b62c481
`68e92f
`
`70523
`
`14
`
`Non Patent Literature
`
`Small_2002.pdf
`
`no
`
`8
`
`Warnings:
`
`Information:
`
`777a603fb0b19562a66c525571b8108210c
`829a2
`
`1645292
`
`15
`
`Non Patent Literature
`
`Smilek_1991.pdf
`
`no
`
`5
`
`a604ec7f03b90bf8fd3c8882dedce3c7b3fc
`802d
`
`Warnings:
`
`Information:
`
`16
`
`Non Patent Literature
`
`Stephenson_The_latest_uses.
`of_Restasis.pdf
`
`2875746
`
`c5d5cdd66d2f333c39c173e5e665d5bacd0
`Oedad
`
`no
`
`7
`
`Warnings:
`
`Information:
`
`17
`
`Non Patent Literature
`
`Stevenson_2000.pdf
`
`no
`
`8
`
`255058
`
`2f70a01929808bc46f5e822eb9cfcc28fcea7
`ab4
`
`Warnings:
`
`Information:
`
`18
`
`Non Patent Literature
`
`TesavibulTopicalCyclosporinel
`996.pdf
`
`56707
`
`no
`
`1
`
`fc4bba0a0ffd0194e2146e1e1dbb52551410
`edeb
`
`Warnings:
`
`Information:
`
`19
`
`Non Patent Literature
`
`Medical_Dictionary_2005.pdf
`
`no
`
`6
`
`670357
`
`2816eb8d1deb894d8911bacd15ed728364
`426c81
`
`Warnings:
`
`Information:
`
`0414
`
`

`

`20
`
`Non Patent Literature
`
`USP-1990.pdf
`
`no
`
`8
`
`2071579
`
`e03560775cf2f863fb6a6247cb268f5de039
`0b60
`
`Warnings:
`
`Information:
`
`21
`
`Non Patent Literature
`
`Tibell_Cyclosporin_A_in_Fat_E
`mulsion_115_121_76.pdf
`
`697241
`
`5c1942bd49b4119100efa0409c42cda5c71
`82d19
`
`no
`
`7
`
`Warnings:
`
`Information:
`
`22
`
`Non Patent Literature
`
`Tsubota_1998.pdf
`
`no
`
`10
`
`2353818
`
`Warnings:
`
`Information:
`
`f0929e8a59cf1006529e4db58b285eec963
`bScOe
`
`2709253
`
`23
`
`Non Patent Literature
`
`Van_der_Reijden_1999.pdf
`
`no
`
`9
`
`Warnings:
`
`Information:
`
`daff1e358e3501bdaae2d9ea3dbc422c6cd
`dalaf
`
`1534440
`
`24
`
`Non Patent Literature
`
`Wiederholt-1986.pdf
`
`no
`
`6
`
`Warnings:
`
`Information:
`
`7a1f27312cc464030a5d8f700cd70c3be91 c
`fadl
`
`1231303
`
`25
`
`Non Patent Literature
`
`Winter_1993.pdf
`
`no
`
`4
`
`Warnings:
`
`Information:
`
`441701043d7f2a34aab980c3e2a2b0db53e
`b3d7f
`
`2596695
`
`26
`
`Non Patent Literature
`
`13961828.pdf
`
`no
`
`34
`
`Warnings:
`
`Information:
`
`660e95b406b8f6ac91600605af4712d74c8f
`77bb
`
`1904560
`
`27
`
`Non Patent Literature
`
`90009944.pdf
`
`no
`
`39
`
`4b5aa1 ab68a1940d5930d4265e9053cf672
`03dc9
`
`Warnings:
`
`Information:
`
`Total Files Size (in bytes):
`
`42267504
`
`0415
`
`

`

`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`0416
`
`

`

`Doc code: IDS
`Doc description: Information Disclosure Statement (IDS) Filed
`
`Application Number
`
`14222478
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Filing Date
`First Named Inventor ANDREW ACHEAMPONG
`1621
`
`2014-03-21
`
`Art Unit
`
`Examiner Name
`Attorney Docket Number
`
`TBD
`
`17618-US-CN6CN1 -AP
`
`U.S.PATENTS
`
`Examiner Cite
`Initial*
`No
`
`Patent Number
`
`Kind
`Code1
`
`Issue Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`1
`
`3278447
`
`1966-10-11
`
`Thomas McNicholas
`
`2
`
`4388229
`
`1983-06-14
`
`Cherng-Chyi Fu
`
`3
`
`4388307
`
`1983-06-14
`
`Thomas Cavanak
`
`4
`
`4614736
`
`1986-09-30
`
`Delevallee et al
`
`5
`
`4649047
`
`1987-03-10
`
`Renee Kaswan
`
`6
`
`4764503
`
`1988-08-16
`
`Roland Wenger
`
`7
`
`4814323
`
`1989-03-21
`
`Andrieu et al
`
`8
`
`4839342
`
`1989-06-13
`
`Renee Kaswan
`
`0417
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`9
`
`4970076
`
`1990-11-13
`
`David Horrobin
`
`10
`
`4990337
`
`1991-02-05
`
`Kurihara et al
`
`11
`
`4996193
`
`1991-02-26
`
`Hewitt et al
`
`12
`
`5011681
`
`1991-04-30
`
`Ciotti et al
`
`13
`
`5047396
`
`1991-09-10
`
`Orban et al
`
`14
`
`5051402
`
`1991-09-24
`
`Kurihara et al
`
`15
`
`5053000
`
`1991-10-01
`
`Booth et al
`
`16
`
`5075104
`
`1991-12-24
`
`Gressel et al
`
`17
`
`5286730
`
`1994-02-15
`
`Caufield et al
`
`18
`
`5286731
`
`1994-02-15
`
`Caufield et al
`
`19
`
`5294604
`
`1994-03-15
`
`Nussenblatt et al
`
`0418
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`20
`
`5296158
`
`1994-03-22
`
`MacGilp et al
`
`21
`
`5342625
`
`1994-08-30
`
`Hauer et al
`
`22
`
`5364632
`
`1994-11-15
`
`Simon Benita
`
`23
`
`5368854
`
`1994-11-29
`
`Donna Rennick
`
`24
`
`5411952
`
`1995-05-02
`
`Renee Kaswan
`
`25
`
`5424078
`
`1995-06-13
`
`Anthony Dziabo
`
`26
`
`5441732
`
`1995-08-15
`
`Hoeg et al
`
`27
`
`5474919
`
`1995-12-12
`
`Chartrain et al
`
`28
`
`5474979
`
`1995-12-12
`
`Ding et al
`
`U.S. Application No. 08/243,279 and
`its entire prosecution history**
`
`29
`
`5496811
`
`1996-03-05
`
`Aviv et al
`
`30
`
`5504068
`
`1996-04-02
`
`Komiya et al
`
`0419
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`31
`
`5540931
`
`1996-07-30
`
`Hewitt et al
`
`32
`
`5543393
`
`1996-08-06
`
`Kim et al
`
`33
`
`5589455
`
`1996-12-31
`
`Jong Woo
`
`34
`
`5591971
`
`1997-01-07
`
`Shahar et al
`
`35
`
`5614491
`
`1997-03-25
`
`Walch et al
`
`36
`
`5639724
`
`1997-06-17
`
`Thomas Cavanak
`
`37
`
`5652212
`
`1997-07-29
`
`Cavanak et al
`
`38
`
`5719123
`
`1998-02-17
`
`Morley et al
`
`39
`
`5721273
`
`1998-02-24
`
`Sallee et al
`
`40
`
`5739105
`
`1998-04-14
`
`Kim et al
`
`41
`
`5753166
`
`1998-05-19
`
`Dalton et al
`
`0420
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`42
`
`5766629
`
`1998-06-16
`
`Cho et al
`
`43
`
`5798333
`
`1998-08-25
`
`Bernard Sherman
`
`44
`
`5807820
`
`1998-09-15
`
`Elias et al
`
`45
`
`5827822
`
`1998-10-27
`
`Floch'h et al
`
`46
`
`5827862
`
`1998-10-27
`
`Yoshitaka Yamamura
`
`47
`
`5834017
`
`1998-11-10
`
`Cho et al
`
`48
`
`5843452
`
`1998-12-01
`
`Wiedmann et al
`
`49
`
`5843891
`
`1998-12-01
`
`Bernard Sherman
`
`50
`
`5858401
`
`1999-01-12
`
`Bhalani et al
`
`51
`
`5866159
`
`1999-02-02
`
`Hauer et al
`
`52
`
`5891846
`
`1999-04-06
`
`Ishida et al
`
`0421
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`53
`
`5916589
`
`1999-06-29
`
`Hauer et al
`
`54
`
`5929030
`
`1999-07-27
`
`Hamied et al
`
`55
`
`5951971
`
`1999-09-14
`
`Kawashima et al
`
`56
`
`5962014
`
`1999-10-05
`
`Hauer et al
`
`57
`
`5962017
`
`1999-10-05
`
`Hauer et al
`
`58
`
`5962019
`
`1999-10-05
`
`Cho et al
`
`59
`
`5977066
`
`1999-11-02
`
`Thomas Cavanak
`
`60
`
`5981479
`
`1999-11-09
`
`Ko et al
`
`61
`
`5981607
`
`1999-11-09
`
`Ding et al
`
`U.S. Application No. 09/008,924 and
`its entire prosecution history**
`
`62
`
`5998365
`
`1999-12-07
`
`Bernard Sherman
`
`63
`
`6004566
`
`1999-12-21
`
`Friedman et al
`
`0422
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`64
`
`6007840
`
`1999-12-28
`
`Hauer et al
`
`65
`
`6008191
`
`1999-12-28
`
`Amarjit Singh
`
`66
`
`6008192
`
`1999-12-28
`
`Al-Razzak et al
`
`67
`
`6022852
`
`2000-02-08
`
`Klokkers et al
`
`68
`
`6024978
`
`2000-02-15
`
`Hauer et al
`
`69
`
`6046163
`
`2000-04-04
`
`Stuchlik et al
`
`70
`
`6057289
`
`2000-05-02
`
`Nirmal Mulye
`
`71
`
`6159933
`
`2000-12-12
`
`Bernard Sherman
`
`72
`
`6197335
`
`2001-03-06
`
`Bernard Sherman
`
`73
`
`6254860
`
`2001-07-03
`
`Michael Garst
`
`74
`
`6254885
`
`2001-07-03
`
`Cho et al
`
`0423
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`75
`
`6267985
`
`2001-07-31
`
`Chen et al
`
`76
`
`6284268
`
`2001-09-04
`
`Mishra et al
`
`77
`
`6294192
`
`2001-09-25
`
`Patel et al
`
`78
`
`6306825
`
`2001-10-23
`
`Thomas Cavanak
`
`79
`
`6323204
`
`2001-11-27
`
`James Burke
`
`80
`
`6346511
`
`2002-02-12
`
`Singh et al
`
`81
`
`6350442
`
`2002-02-26
`
`Michael Garst
`
`82
`
`6413547
`
`2002-07-02
`
`Bennett et al
`
`83
`
`6420355
`
`2002-07-16
`
`Richter et al
`
`84
`
`6468968
`
`2002-10-22
`
`Cavanak et al
`
`85
`
`6475519
`
`2002-11-05
`
`Meinzer et al
`
`0424
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`86
`
`6486124
`
`2002-11-26
`
`Olbrich et al
`
`87
`
`6544953
`
`2003-04-08
`
`Tsuzuki et al
`
`88
`
`6555526
`
`2003-04-29
`
`Matsuo et al
`
`89
`
`6562873
`
`2003-05-13
`
`Olejnik et al
`
`90
`
`6569463
`
`2003-05-27
`
`Patel et al
`
`91
`
`6582718
`
`2003-06-24
`
`Yoichi Kawashima
`
`92
`
`6656460
`
`2003-12-02
`
`Benita et al
`
`93
`
`6872705
`
`2005-03-29
`
`Robert Lyons
`
`94
`
`6984628
`
`2006-01-10
`
`Bakhit et al
`
`95
`
`7202209
`
`2007-04-10
`
`James N. Chang
`
`96
`
`7276476
`
`2007-10-02
`
`Chang et al
`
`U.S. Application No. 11/181,428 and
`its entire prosecution history**
`
`U.S. Application No. 11/181,187 and
`its entire prosecution history**
`
`0425
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`97
`
`7288520
`
`2007-10-30
`
`Chang et al
`
`98
`
`7297679
`
`2007-11-20
`
`James Chang
`
`99
`
`7501393
`
`2009-03-10
`
`Tien et al
`
`100
`
`8211855
`
`2012-07-03
`
`Chang et al
`
`101
`
`8288348
`
`2012-10-16
`
`Chang et al
`
`102
`
`8618064
`
`2013-12-31
`
`Acheampong et al
`
`103
`
`8629111
`
`2014-01-14
`
`Acheampong et al
`
`104
`
`8633162
`
`2014-01-21
`
`Acheampong et al
`
`105
`
`8642556
`
`2014-02-04
`
`Acheampong et al
`
`106
`
`8648048
`
`2014-02-11
`
`Acheampong et al
`
`If you wish to add additional U.S. Patent citation information please click the Add button.
`U.S.PATENT APPLICATION PUBLICATIONS
`
`U.S. Application No. 11/255,821 and
`its entire prosecution history**
`
`U.S. Application No. 11/181,178 and
`its entire prosecution history**
`
`U.S. Application No. 11/161,218 and
`its entire prosecution history**
`
`U.S. Application No. 11/857,223 and
`its entire prosecution history**
`
`U.S. Application No. 11/917,448 and
`its entire prosecution history**
`
`U.S. Application No. 11/897,177 and
`its entire prosecution history**
`
`U.S. Application No. 13/967,163 and
`its entire prosecution history**
`
`U.S. Application No. 13/967,179 and
`its entire prosecution history**
`
`U.S. Application No. 13/967,189 and
`its entire prosecution history**
`
`U.S. Application No. 13/967,168 and
`its entire prosecution history**
`
`0426
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`Examiner
`Initial*
`
`Cite No
`
`Publication
`Number
`
`Kind Publication
`Code1 Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`20010003589
`
`2001-06-14
`
`Neuer et al
`
`20010014665
`
`2001-08-16
`
`Fischer et al
`
`20010036449
`
`2001-11-01
`
`Michael Garst
`
`20020012680
`
`2002-01-31
`
`Patel et al
`
`20020013272
`
`2002-01-31
`
`Cavanak et al
`
`20020016290
`
`2002-02-07
`
`Floc'h et al
`
`20020016292
`
`2002-02-07
`
`Richter et al
`
`20020025927
`
`2002-02-28
`
`Olbrich et al
`
`20020045601
`
`2002-04-18
`
`Yoichi Kawashima
`
`10
`
`20020107183
`
`2002-08-08
`
`Petszulat et al
`
`0427
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`11
`
`20020119190
`
`2002-08-29
`
`Meinzer et al
`
`12
`
`20020165134
`
`2002-11-07
`
`Richter et al
`
`13
`
`20030021816
`
`2003-01-30
`
`Kang et al
`
`14
`
`20030044452
`
`2003-03-06
`
`Ryuji Ueno
`
`15
`
`20030055028
`
`2003-03-20
`
`Stergiopoulos et al
`
`16
`
`20030059470
`
`2003-03-27
`
`Rainer Muller
`
`17
`
`20030060402
`
`2003-03-27
`
`Cavanak et al
`
`18
`
`20030087813
`
`2003-05-08
`
`Or et al
`
`19
`
`20030104992
`
`2003-06-05
`
`Or et al
`
`20
`
`20030108626
`
`2003-06-12
`
`Benita et al
`
`21
`
`20030109425
`
`2003-06-12
`
`Or et al
`
`0428
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`22
`
`20030109426
`
`2003-06-12
`
`Or et al
`
`23
`
`20030133984
`
`2003-07-17
`
`Ambuhl et al
`
`24
`
`20030143250
`
`2003-07-31
`
`Hauer et al
`
`25
`
`20030147954
`
`2003-08-07
`
`Yang et al
`
`26
`
`20030166517
`
`2003-09-04
`
`Fricker et al
`
`27
`
`20050014691
`
`2005-01-20
`
`Bakhit et al
`
`28
`
`20050059583
`
`2005-03-17
`
`Andrew Acheampong
`
`U.S. Application No. 10/927,857 and
`its entire prosecution history**
`
`29
`
`20070015691
`
`2007-01-18
`
`James Chang
`
`U.S. Application No. 11/181,409 and
`its entire prosecution history**
`
`30
`
`20070027072
`
`2007-02-01
`
`Tien et al
`
`31
`
`20070087962
`
`2007-04-19
`
`Tien et al
`
`32
`
`20070149447
`
`2007-06-28
`
`Chang et al
`
`U.S. Application No. 11/679,934 and
`its entire prosecution history**
`
`0429
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`33
`
`20080039378
`
`2008-02-14
`
`Graham et al
`
`34
`
`20080070834
`
`2008-03-20
`
`Chang et al
`
`35
`
`20080146497
`
`2008-06-19
`
`Graham et al
`
`36
`
`20080207495
`
`2008-08-28
`
`Graham et al
`
`37
`
`20090131307
`
`2009-05-21
`
`Tien et al
`
`38
`
`20100279951
`
`2010-11-04
`
`Morgan et al
`
`39
`
`20110009339
`
`2011-01-13
`
`Rhett Schiffman
`
`40
`
`20110294744
`
`2011-12-01
`
`Morgan et al
`
`41
`
`20120270805
`
`2012-10-25
`
`Chang et al
`
`42
`
`20130059796
`
`2013-03-07
`
`Chang et al
`
`U.S. Application No. 11/781,095 and
`its entire prosecution history**
`
`U.S. Application No. 11/940,652 and
`its entire prosecution history**
`
`U.S. Application No. 11/858,200 and
`its entire prosecution history**
`
`U.S. Application No. 12/035,698 and
`its entire prosecution history**
`
`U.S. Application No. 12/361,335 and
`its entire prosecution history**
`
`U.S. Application No. 12/771,952 and
`its entire prosecution history**
`
`U.S. Application No. 12/759,431 and
`its entire prosecution history**
`
`U.S. Application No. 13/115,764 and
`its entire prosecution history**
`
`U.S. Application No. 13/536,479 and
`its entire prosecution history**
`
`U.S. Application No. 13/649,287 and
`its entire prosecution history**
`
`If you wish to add additional U.S. Published Application citation information please click the Add button.
`FOREIGN PATENT DOCUMENTS
`
`0430
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`Examiner Cite
`Initial*
`No
`
`Foreign Document
`Number3
`
`Country
`Code2!
`
`Kind Publication
`Code4 Date
`
`Name of Patentee or
`Applicant of cited
`Document
`
`Pages,Columns, Lines
`where Relevant
`Passages or Relevant
`Figures Appear
`
`T5
`
`1
`
`19810655
`
`DE
`
`1999-09-16
`
`Eberhard-Karis-
`Universitat Tubingen
`Universitatskl
`
`2
`
`0448856
`
`3
`
`0471293
`
`4
`
`0480690
`
`5
`
`0547229
`
`6
`
`0760237
`
`EP
`
`EP
`
`EP
`
`EP
`
`EP
`
`1991-10-02
`
`Chatfield Pharmaceuticals
`
`1992-02-19
`
`ABBOTT
`LABORATORIES
`
`1992-04-15
`
`IOLAB CORPORATION
`
`1993-01-07
`
`LLT Institute Co., Ltd.
`
`1997-03-05
`
`Cipla Limited
`
`7
`
`1995-031211
`
`WO
`
`1995-11-23
`
`Allergan, Inc.
`
`8
`
`2000-000179
`
`WO
`
`2000-01-06
`
`Won Jin Biopharma Co.,
`Ltd
`
`9
`
`2001-032142
`
`WO
`
`2001-05-10
`
`Cipla Limited
`
`10
`
`2001-041671
`
`WO
`
`2001-06-14
`
`Transneuronix, Inc.
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`0431
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`11
`
`2002-009667
`
`WO
`
`2002-02-07
`
`Pharmasol GMBH
`
`12
`
`2002-049603
`
`WO
`
`2002-06-27
`
`LG Household & Health
`Care Ltd.
`
`13
`
`2003-030834
`
`WO
`
`2003-04-17
`
`Enanta Pharmaceuticals,
`Inc.
`
`14
`
`2003-053405
`
`WO
`
`2003-07-03
`
`Yissum Research
`Development Company of
`the Hebrew
`
`•
`
`•
`
`•
`
`•
`
`If you wish to add additional Foreign Patent Document citation information please click the Add button
`NON-PATENT LITERATURE DOCUMENTS
`
`Examiner Cite
`Initials* No
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`publisher, city and/or country where published.
`
`T5
`
`1
`
`2
`
`3
`
`4
`
`5
`
`ABDULRAZIK, M. ET AL, Ocular Delivery of Cyclosporin A II. Effect of Submicron Emulsion's Surface Charge on
`Ocular Distribution of Topical Cyclosporin A, S.T.P. Pharma Sciences, Dec. 2001, 427-432, 11(6)
`
`ACHEAMPONG, ANDREW ET AL, Cyclosporine Distribution into the Conjunctiva, Cornea, Lacrimal Gland and
`Systemic Blood Following Topical Dosing of Cyclosporine to Rabbit, Dog and Human eyes, 1996, 179
`
`•
`
`•
`
`ACHEAMPONG, ANDREW ET AL, Cyclosporine Distribution Into The Conjunctiva, Cornea, Lacrimal Gland, and
`
`Systemic Blood Following Topical Dosing of Cyclosporine to Rabbit, Dog, and Human Eyes, Adv. Exp. Med. Biol., •
`
`1998, 1001-1004, 438
`
`ACHEAMPONG, ANDREW ET AL, Distribution of Cyclosporin A in Ocular Tissues After Topical Administration to •
`
`Albino Rabbits and Beagle Dogs, Current Eye Research, 1999, 91-103, 18(2)
`
`AKPEK, ESEN KARAMURSEL ET AL, A Randomized Trial of Topical Cyclosporin 0.05% in Topical Steroid-Resistant
`Atopic Keratoconjunctivitis, Ophthalmology, 2004, 476-482, 111
`
`•
`
`0432
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`6
`
`7
`
`8
`
`9
`
`ANGELOV, O. ET AL, Preclinical Safety Studies of Cyclosporine Ophthalmic Emulsion, Adv Exp Med Biol, 1998,
`991-995, 438
`
`ANGELOV, O. ET AL, Safety Assessment of Cyclosporine Ophthalmic Emulsion in Rabbits and Dogs, Xlth Congress
`of the European Society of Ophthalmology, 1997, 25-28, 1-5, Soc. Ophthalmol Eur., HU
`
`ARDIZZONE, SANDRO ET AL, A Practical Guide to the Management of Distal Ulcerative Colitis, Drugs, 1998,
`519-542, 55(4)
`
`•
`
`•
`
`•
`
`BANIC, MARKO ET AL, Effect of Cyclosporine in a Murine Model of Experimental Colitis, Digestive Diseases and •
`
`Sciences, June 2002, 1362-1368, 47(6)
`
`10
`
`BF GOODRICH, CARBOPOL 1342 A New Polymer Which Functions Both As a Thickener And An Emulsifier TDS-73, •
`
`Carbopol High Performance Polymers, 1987, 25 Pages
`
`11
`
`BF GOODRICH, Carbopol, Pemulen and Noveon Polymers, 1995, 2 Pages
`
`12
`
`BF GOODRICH, Pemulen Polymeric Emulsifiers TDS-182, March 1993, 9 Pages
`
`13
`
`BONINI, S. ET AL, Vernal Keratoconjunctivitis, Eye, 2004, 345-351, 18
`
`14
`
`BREWSTER, MARCUS ET AL, Enhanced Delivery of Ganciclovir to the Brain Through the Use of Redox Targeting,
`Antimicrobial Agents and Chemotherapy, Apr 1994, 817-823, 38(4)
`
`BREWSTER, MARCUS ET AL, Intravenous and Oral Pharmacokinetic Evaluation of a 2-Hydroxypropyl-(2,-cyclodextrin-
`Based Formulation of Carbamazepine in the Dog: Comparison with Commercially Available Tablets and Suspensions,
`Journal of Pharmaceutical Sciences, March 1997, 335-339, 86(3)
`
`•
`
`•
`
`•
`
`•
`
`•
`
`15
`
`16
`
`BREWSTER, MARCUS ET AL, Preparation, Characterization, and Anesthetic Properties of 2-Hydroxypropyl-(2,-
`
`cyclodextrin Complexes of Pregnanolone and Pregnenolone in Rat and Mouse, Journal of Pharmaceutical Sciences, •
`
`October 1995, 1154-1159, 84(10)
`
`0433
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`17
`
`BRINKMEIER, THOMAS ET AL, Pyodermatitis-Pyostomatitis Vegetans: A Clinical Course of Two Decades with
`Response to Cyclosporine and Low-Dose Prednisolone, Acta Derm Venereol, 2001, 134-136, 81
`
`•
`
`18
`
`19
`
`CASTILLO, JOSE M. BENITEZ DEL ET AL, Influence of Topical Cyclosporine A and Dissolvent on Corneal Epithelium •
`
`Permeability of Fluorescein, Documenta Ophthalmologica, 1995, 49-55, 91
`
`CHEEKS, LISA ET AL, Influence of Vehicle and Anterior Chamber Protein Concentration on Cyclosporine Penetration •
`
`Through the Isolated Rabbit Cornea, Current Eye Research, 1992, 641-649, 11(7)
`
`20
`
`Database WPI Week 200044, Derwent Pub. Ltd., London, GB; An 2000-492678 & JP2000/143542, 2000, 2 Pages
`
`•
`
`21
`
`DING, SHULIN ET AL, Cyclosporine Ophthalmic O/W emulsion: Formulation and Emulsion Characterization, Pharm •
`
`Res, 1997, 1 page, 14 (11)
`
`22
`
`DONNENFELD, ERIC D., The Economics Of Using Restasis, Ophthalmology Management, 10/2003, 3 pages, US
`
`23
`
`DROSOS, A. A. ET AL, Efficacy and Safety of Cyclosporine-A Therapy for Primary Sjogren's Syndrome, Ter. Arkh.,
`1998, 77-80, 60(4)
`
`•
`
`•
`
`24
`
`DROSOS, A.A. ET AL, Cyclosporin A Therapy in Patients with Primary Sjogren's Syndrome: Results at One Year, •
`
`Scand J Rheumatology, 1986, 246-249, 61
`
`25
`
`DURRANI, A.M. ET AL, Pilocarpine Bioavailability From a Mucoadhesive Liposomal Ophthalmic Drug Delivery
`System, International Journal of Pharmaceutics, 1992, 409-415, 88
`
`26
`
`EISEN, DRORE ET AL, Topical Cyclosporine for Oral Mucosal Disorders, J Am Acad Dermatol, Dec. 1990,
`1259-1264, 23
`
`•
`
`•
`
`27
`
`EPSTEIN, JOEL ET AL, Topical Cyclosporine in a Bioadhesive for Treatment of Oral Lichenoid Muscosal Reactions, •
`
`Oral Surg Oral Med Oral Pathol Oral, 1996, 532-536, 82
`
`0434
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`Art Unit
`
`14222478
`
`2014-03-21
`
`ANDREW ACHEAMPONG
`
`1621
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-CN6CN1 -AP
`
`28
`
`ERDMANN, S. ET AL, Pemphigus Vulgaris Der Mund- Und Kehlkopfschleimhaut Pemphigus Vulgaris of the Oral
`Mucosa and the Larynx, H+G Zeitschrift Fuer Hautkrankheiten, 1997, 283-286, 72(4)
`
`29
`
`FDA Concludes Restasis (Cyclosporine) Not Effective for Dry Eye (6/18/1999). Accessed online at http://www.
`dryeyeinfo.org/Restasis_Cyclosporine.htm on 8/14/09. 1 Page
`
`30
`
`GAETA, G.M. ET AL, Cyclosporin Bioadhesive Gel in the Topical Treatment of Erosive Oral Lichen Planus,
`International Journal of Immunopathology and Pharmacology, 1994, 125-132, 7(2)
`
`•
`
`•
`
`•
`
`31
`
`GIPSON, ILENE ET AL, Character of Ocular Surface Mucins and Their Alteration in Dry Eye Disease, The Ocular •
`
`Surface, April 2004, 131-148, 2(2)
`
`32
`
`GREMSE, DAVID ET AL, Ulcerative Colitis in Children, Pediatr Drugs, 2002, 807-815, 4(12)
`
`33
`
`GUNDUZ, KAAN ET AL, Topical Cyclosporin Treatment of Keratoconjunctivitis Sicca in Secondary Sjogren's
`Syndrome, Acta Ophthalmologica, 1994, 438-442, 72
`
`34
`
`http://web.archive.org/web/2001030625323/http://www.surfactant.co.kr/surfactants/pegester.html, 2001, 6 Pages,
`retrieved on 7/05/2008
`
`35
`
`HUNTER, P.A. ET AL, Cyclosporin A Applied Topically to the Recipient Eye Inhibits Corneal Graft Rejection, Clin Exp
`Immunol, 1981, 173-177, 45
`
`36
`
`JUMAA, MUHANNAD ET AL, Physicochemical Properties and Hemolytic Effect of Different Lipid Emulsion
`Formulations Using a Mixture of Emulsifiers, Pharmaceutica Acta Helvetiae, 1999, 293-301, 73
`
`•
`
`•
`
`•
`
`•
`
`•
`
`37
`
`KANAI, A. ET AL, The Effect on the Cornea of Alpha Cyclodextrin Vehicle for Eye Drops, Transplantation Proceedings, •
`
`February 1989, 3150-3152, Vol. 21
`
`38
`
`KANPOLAT, AYFER ET AL, Penetration of Cyclosporin A into the Rabbit Cornea and Aqueous Humor after Topical
`Drop and Collagen Shield Administration, Cornea/External Disease, April 1994, 119-122, 20(2)
`
`•
`
`0435
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPL